广州伟伯科技有限公司
您的位置:首页 > 产品中心 > SILuTMMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody
产品搜索:

SILuTMMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody

产品编号:4090164
规格:recombinant, expressed in CHO cells
包装规格:100 μG
产品类别:进口试剂
品牌:Sigma-Aldrich
优惠价:立即咨询
产品价格
产品编号包装单位单价(元)国内现货国外库存询价单
4090164100 μG4430
产品别名

SILuTMMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody

SIL Infliximab

产品性质
Quality Level【质量水平】
200
recombinant【重组】
expressed in CHO cells
antibody product type
primary antibodies
Assay【测定】
≥90% (SDS-PAGE)
packaging【包装】
vial of 100 μg
shipped in【运输】
wet ice
storage temp.【储存温度】
−20℃
基本信息
General description【一般描述】
SILuMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody (MSQC9) is a recombinant, stable isotope-labeled, monoclonal antibody which incorporates [13C6, 15N4]-Arginine and [13C6, 15N2]-Lysine. Expressed in CHO cells, it is designed to be used as an internal standard for the quantitative mass spectrometry analysis of Infliximab in human serum. Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-a) and is used to treat autoimmune diseases.
Infliximab has been approved for the treatment of Crohn′s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. SILuMAb Infliximab Stable-Isotope Labeled Monoclonal Antibody is for R&D use only. Not for drug, household, or other uses.
Application【应用】
Poster: Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard
Physical form【外形】
Each vial of SILuMab Infliximab Stable-Isotope Labeled Monoclonal Antibody contains the labeled antibody in a lyophilized form containing phosphate buffered saline.
Preparation Note【制备说明】
Produced utilizing enriched media containing stable isotope labeled amino acids are 13C6, 15N4-labeled Arginine and 13C6, 15N2-labeled Lysine.
SILuMab Infliximab Stable-Isotope Labeled Monoclonal Antibody is designed to be used as a internal standard for analysis of Infliximab in human serum.
Reconstitution【重悬】
SILuMab Infliximab recovery is maximized when 0.1% formic acid is used for reconstitution of the lyophilized product.Reconstitution with other solvents may reduce recovery. Do not freeze after reconstitution.

  • Briefly centrifuge the vial at ~10,000 × g to collect the product at the bottom of the vial.
  • Add 500 μL of ultrapure water containing 0.1% formic acid to the vial.
  • Mix the contents by gently inverting the vial a minimum of 5 times.
  • Allow the vial to stand at room temperature for at least 15 minutes and repeat mixing by inversion.
Analysis Note【分析说明】
Quantitative
MRM settings provided (xls)
Legal Information【法律信息】
This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
SILu is a trademark of sigma-aldrich Co. LLC
安全信息
Storage Class Code【储存分类代码】
13 - Non Combustible Solids
WGK
WGK 3
广州伟伯科技有限公司 版权所有 CopyRight ©2006-2024, All Rights Reserved
工信部备案号:粤ICP备08114744号   Page Run Time: 0.0072